Leap Therapeutics Inc LPTX:NASDAQ

Last Price$0.52Cboe Closing Price as of 4:00PM ET 12/05/22
Cboe Real-Time Quotes
Today's Change-0.06(9.70%)
Bid (Size)$0.43 (100)
Ask (Size)$0.68 (100)
Day Low / High$0.52 - 0.58
Volume548.4 K
  • Latest Stories
  • Commentary and Analysis
--Raymond James Adjusts Price Target on Leap Therapeutics to $2.50 From $3.50, Maintains Outperform Rating
10:17AM ET 11/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Leap Therapeutics Enrolls First Patient in Phase 2 Study of Colorectal Cancer Combination Therapy
7:59AM ET 10/17/2022 MT Newswires

Leap Therapeutics (LPTX) said Monday the first patient has been enrolled in its Phase 2 trial evaluating a potential combination treatment for patients...

Leap Therapeutics Begins Patient Enrollment in Part C of Phase 2 Study to Assess Antibody Combination to Treat Gastric, Gastroesophageal Junction Cancer
8:37AM ET 10/12/2022 MT Newswires

Leap Therapeutics (LPTX) said Wednesday it has begun the enrollment of patients in the part C of a phase 2 study to assess its DKN-01 antibody combined...

Raymond James Adjusts Leap Therapeutics' Price Target to $3 from $4, Keeps Outperform Rating
11:06AM ET 7/13/2022 MT Newswires

Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $3 to $6, according to analysts polled by Capital IQ. (MT...

Leap Therapeutics, BeiGene Initiate New DKN-01 Trials for Cancers
7:47AM ET 7/12/2022 MT Newswires

Leap Therapeutics (LPTX) and BeiGene, Ltd (BGNE) said Tuesday that they have initiated Part C of an ongoing study on Leap's treatment DKN-01 in combination...

Piper Sandler Adjusts Leap Therapeutics' Price Target to $4 From $6, Reiterates Overweight Rating
5:14AM ET 5/31/2022 MT Newswires

Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $4 to $6, according to analysts polled by Capital IQ. (MT...

Leap Therapeutics, Leica Team Up to Develop Companion Diagnostic for Cancer Patients
7:51AM ET 1/31/2022 MT Newswires

Leap Therapeutics (LPTX) said Monday that it has teamed up with Leica Biosystems to develop a companion diagnostic to detect Dickkopf-related protein 1....

--Piper Sandler Adjusts Leap Therapeutics' Price Target to $6 From $5, Reiterates Overweight Rating
5:05AM ET 1/24/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
9:12AM ET 1/19/2022 MT Newswires

Health care stocks were edging higher premarket Wednesday. The iShares Biotechnology ETF (IBB) was up by 0.64% while the Health Care SPDR (XLV) was 0.02%...

Leap Therapeutics to Report 'Encouraging Results' From Phase 2a Trial of Combination Treatment for Gastric Cancer -- Shares Jump in Pre-Market
6:06AM ET 1/19/2022 MT Newswires

Leap Therapeutics (LPTX) said late on Tuesday the combination of anti-Dickkopf-1, or DKN-01, with tislelizumab "continues to demonstrate encouraging...